Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

[1]  M. Mason,et al.  A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. , 2009, Vaccine.

[2]  H. Xiong,et al.  TLR signaling by tumor and immune cells: a double-edged sword , 2008, Oncogene.

[3]  K. Mills,et al.  TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours , 2008, Oncogene.

[4]  H. Markholst,et al.  PolyI:C Induction of Diabetes Is Controlled by Iddm4 in Rats with a Full Regulatory T Cell Pool , 2007, Annals of the New York Academy of Sciences.

[5]  R. Flavell,et al.  TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules1 , 2007, The Journal of Immunology.

[6]  S. H. van der Burg,et al.  Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. , 2007, Vaccine.

[7]  K. Hoebe,et al.  Cell-Associated Double-Stranded RNA Enhances Antitumor Activity through the Production of Type I IFN1 , 2006, The Journal of Immunology.

[8]  J. Aerts,et al.  Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA , 2006, Gene Therapy.

[9]  Michael Y. Gerner,et al.  Signals required for programming effector and memory development by CD8+ T cells , 2006, Immunological reviews.

[10]  C. Sousa,et al.  Dendritic cells in a mature age , 2006, Nature Reviews Immunology.

[11]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[12]  N. Restifo,et al.  The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. , 2006, Cancer research.

[13]  M. Mason,et al.  The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. , 2005, Vaccine.

[14]  N. Klimas,et al.  Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:PolyC12U in the treatment of HIV infection , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  J. Kirkwood,et al.  alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.

[16]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[17]  S. Bellone,et al.  Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[18]  J. Curtsinger,et al.  CD8 T Cell Clonal Expansion and Development of Effector Function Require Prolonged Exposure to Antigen, Costimulation, and Signal 3 Cytokine 1 , 2003, The Journal of Immunology.

[19]  B. Czerniecki,et al.  Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism 1 , 2003, The Journal of Immunology.

[20]  A. Fiander,et al.  Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). , 2003, Vaccine.

[21]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[22]  A. Sher,et al.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. , 2000, Immunity.

[23]  R. Verdijk,et al.  Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. , 1999, Journal of immunology.

[24]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[25]  M. de Boer,et al.  Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. , 1997, Blood.

[26]  R. Steinman,et al.  Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.

[27]  E. Engleman,et al.  Generation of antigen-specific CD8+ CTLs from naive precursors. , 1994, Journal of immunology.

[28]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[29]  S. Ida,et al.  In vivo antiviral effects of mismatched double‐stranded RNA on duck hepatitis B virus , 1994, Journal of medical virology.

[30]  M. Loveless,et al.  A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  V. Devita,et al.  A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. , 1976, Journal of the National Cancer Institute.